DRKS00031154招募中不适用
Circulating DNA for treatment and follow-up in squamous cell cancers
Asklepios Tumorzentrum Hamburg0 个研究点目标入组 600 人开始时间: 2023年2月22日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Histopathologically verified SCC
- •Eligible for curatively or palliatively intended treatment
- •= 18 of years
- •Written and oral consent
排除标准
- •Other cancer disease within 5 year of SCC diagnosis
- •Conditions that will contraindicate blood samples
- •Potential lack of compliance to standard FU program and study participation.
研究者
相似试验
已完成
不适用
Exploring the utility of circulating tumor DNA in neoadjuvant settingCTRI/2016/09/007308DEPARTMENT OF BIOTECHNOLOGY15
已完成
不适用
Prospective Evaluation of Circulating Tumour DNA (ctDNA) as Molecular Monitoring Tool and Prognostic Biomarker in Resectable Pancreatic AdenocarcinomasC25Malignant neoplasm of pancreasDRKS00010992niversitätsklinikum Freiburg25
终止
不适用
DETECTION Trial: Using blood tests to guide early treatment of relapse in early stage melanomaMalignant neoplasm: skinSkin CancerCancerISRCTN94991276Christie Hospital NHS Foundation Trust8
招募中
不适用
Circulating tumor DNA for minimal residual disease in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant: a multi-center prospective study.Acute Myeloid Leukemia, Myelodysplastic SyndromesJPRN-UMIN000033003Kanto Study Group for Cell Therapy70
已完成
不适用
ctDNA as a Biomarker for Treatment Response in HNSCCCarcinoma, Squamous Cell of Head and NeckNCT03540563The Netherlands Cancer Institute70